Overview

Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation

Status:
Completed
Trial end date:
2019-05-01
Target enrollment:
Participant gender:
Summary
In this study, the investigator's want to find out if dabrafenib can stop stage IIIC melanoma from coming back after surgery.
Phase:
Phase 2
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborators:
National Comprehensive Cancer Network
Novartis
Treatments:
Dabrafenib